

# AIM ImmunoTech Inc.

17:30 14 Jun 2019

## Hemispherx Biopharma initiated with a Buy rating and \$8 price target at Maxim

Analysts at Maxim Group initiated coverage Friday of Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) with a Buy rating and \$8 price target on the stock.

At the core of the promising Ocala, Florida-based company's pipeline is its flagship drug Ampligen (rintatolimod), an experimental ribonucleic acid that is in clinical trials to address both chronic fatigue syndrome and to treat multiple cancers.

"We are initiating coverage of Hemispherx Biopharma with a Buy rating and a \$8 price target," wrote Maxim Group analyst Jason McCarthy in a note to clients.

That represented a 53% upside as the stock is currently trading at \$5.22.

**READ:** Hemispherx treats first patient with cancer drug Ampligen in Phase 2 clinical trials

"The company's lead asset is Ampligen, a unique TLR3 agonist that reprograms the tumor microenvironment to become more responsive to other therapies, including checkpoints," he added.

Given Ampligen's strength in battling solid tumors, there are a series of cancer trials in various stages underway at major research hospitals. The studies are evaluating whether the combination of ampligen with checkpoint blockade therapies (powerful immunotherapy drugs that block proteins that restrain the body's immune system from fighting cancer) will improve clinical tumor responses, time to progression and survival rates.

**Upcoming data readouts**

"Multiple early stage combination studies ongoing; a P1/2 and P2 in ovarian cancer, a P2 in triple negative breast cancer, and a P2a in colorectal cancer w/ liver mets and an expanded access program in pancreatic cancer (monotherapy)," wrote McCarthy.

"Data updates expected in 2019/20, as well as additional new studies initiating," he added.

Hemispherx took a key step forward in its Phase 2 clinical trial on Wednesday after it announced that the first patient has been treated with its flagship drug Ampligen.

The study looks at the effectiveness of Ampligen in combination with the drug pembrolizumab at treating ovarian cancer. It is being run out of the University of Pittsburgh Medical Center.

Hemispherx believes that Ampligen could have anti-viral and anti-cancer properties. Prior clinical trials of the drug looked at patients with renal cell carcinoma and malignant melanoma.

**Bullish view**

**Price:** 0.421

**Market Cap:** \$3.48 m

### 1 Year Share Price Graph



December 2018 June 2019 December 20

### Share Information

**Code:** AIM

**Listing:** NYSE

<b>52 week</b>	<b>High</b>	<b>Low</b>
	<b>14.8104</b>	<b>0.39</b>

**Sector:** Pharma & Biotech

**Website:** aimimmuno.com

### Company Synopsis:

*AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders.*

action@proactiveinvestors.com

McCarthy was unequivocal about the potential upside Hemispherx offered early investors.

"As the immune-oncology (IO) space continues to grow from checkpoints and CART to vaccines, what's become more clear is that unlocking the larger market opportunities is going to take combinations, and sets the stage for Ampligen," he wrote.

"With a \$10M valuation and data updates expected over 2019 and 2020, which if positive, could demonstrate proof concept, we see upside," he added.

Contact Uttara Choudhury at [uttara@proactiveinvestors.com](mailto:uttara@proactiveinvestors.com)

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

#### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).